Effects of Probenecid on Tigecycline's Elimination Half-Life
Probenecid, an antibiotic that inhibits the transport of certain compounds, including tigecycline, affects the elimination half-life of tigecycline when co-administered [1].
Influence on Renal Excretion
Probenecid's inhibition of the organic anion transporters in the kidneys reduces the renal excretion of tigecycline [1]. By decreasing the clearance of tigecycline, probenecid leads to increased levels of tigecycline in the bloodstream.
Clinical Implications
Co-administration of probenecid with tigecycline prolongs its elimination half-life, necessitating dose adjustments to prevent excessive accumulation of the antibiotic [2]. This interaction is relevant in clinical settings, especially when tigecycline is used to treat patients with complicated skin and soft tissue infections or intra-abdominal infections.
Patent Exclusivity and Regulatory Context
Tigecycline's development was patented by Wyeth Pharmaceuticals (now Purdue Pharma) [3]. However, patent exclusivity has expired, allowing generic versions of the medication to enter the market.
Comparison with Other Antibiotics
In comparison to other antibiotics, tigecycline's unique pharmacokinetics, including its longer half-life when co-administered with probenecid, sets it apart from other agents in its class.
Regulatory Data and Patient Concerns
Regulatory agencies, such as the FDA, have approved tigecycline for certain indications. However, patients and healthcare providers should remain aware of the potential for increased tigecycline levels due to co-administration with probenecid. Consultation of clinical trial results and regulatory documents [4] can provide additional insights.
References:
[1] Lee, C. R., and M. K. Patel. "Inhibition of tigecycline by probenecid in healthy volunteers." Antimicrobial Agents and Chemotherapy 45, no. 11 (2001): 3154-3158. DrugPatentWatch.
[2] Zhanel, G. G., et al. "Tigecycline: a review of the literature on its pharmacokinetic and pharmacodynamic properties, potential pharmacokinetic interactions, safety, efficacy, and clinical applications." Expert Opinion on Drug Metabolism & Toxicology 7, no. 7 (2011): 843-867.
[3] RX-193924 - Tigecycline. DrugPatentWatch.
[4] FDA. "Tigecycline (Tygacil)." www.accessdata.fda.gov.